33 completed, 1 withdrawn. 34 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 34 | Completed 33, Withdrawn 1 |
Follow Acellular Pertussis: new trials by email Literature Review of Acellular Pertussis trials Research Report on Acellular Pertussis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants Infanrix-IPV/Hib - Diphtheria, Acellular Pertussis | Phase 3 | Withdrawn | GlaxoSmithKline | 2017-12-01 | 2017-12-26 | |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Infanrix hexa, Pediarix, ActHIB - Poliomyelitis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 585 | 2014-04-16 | 2019-11-27 |
| Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children Boostrix™ - Diphtheria, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 302 | 2014-02-22 | 2018-08-02 |
| Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults Boostrix - Tetanus, Acellular Pertussis | Phase 3 | Completed | GlaxoSmithKline | 165 | 2013-01-31 | 2018-06-06 |
| Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers Infanrix-IPV+Hib™ - Acellular Pertussis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 321 | 2012-12-08 | 2020-01-21 |
| Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine Infanrix hexa™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 224 | 2012-04-16 | 2020-01-02 |
| Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine Infanrix+Hib™, Poliorix™ - Acellular Pertussis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 831 | 2011-10-01 | 2018-06-06 |
| Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children Boostrix PolioTM, RepevaxTM, PriorixTM - Acellular Pertussis, Poliomyelitis | Phase 3 | Completed | GlaxoSmithKline | 387 | 2011-04-01 | 2018-08-17 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine Infanrix™-IPV+Hib, Infanrix™ IPV, Hiberix™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 454 | 2011-03-04 | 2019-11-27 |
| Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine Infanrix-IPV/Hib™, Infanrix Hib™, Poliorix™ - Tetanus, Poliomyelitis | Phase 3 | Completed | GlaxoSmithKline | 985 | 2010-03-01 | 2018-06-06 |
| Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) Infanrix™-IPV/Hib - Haemophilus Influenzae Type b, Acellular Pertussis | Phase 3 | Completed | GlaxoSmithKline | 50 | 2009-12-01 | 2018-06-06 |
| Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. Boostrix Polio™ 711866, Priorix Tetra TM 208136, Tetravac TM - Acellular Pertussis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 303 | 2009-04-01 | 2018-06-06 |
| Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax - Tetanus, Acellular Pertussis | Phase 3 | Completed | GlaxoSmithKline | 478 | 2009-03-31 | 2018-08-22 |
| Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine. Boostrix®, Decavac™ - Tetanus, Acellular Pertussis | Phase 3 | Completed | GlaxoSmithKline | 1332 | 2009-02-17 | 2020-01-03 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children Infanrix™, Hiberix™ - Acellular Pertussis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 467 | 2008-06-07 | 2018-06-06 |
| Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 Taking of blood samples, Boostrix, Adacel - Acellular Pertussis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 1954 | 2007-06-01 | 2020-05-01 |
| Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Infanrix hexa - Hepatitis B, Acellular Pertussis | Phase 3 | Completed | GlaxoSmithKline | 1437 | 2007-04-25 | 2020-01-02 |
| Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine Boostrix, Chinese DT vaccine - Diphtheria, Acellular Pertussis | Phase 3 | Completed | GlaxoSmithKline | 660 | 2007-03-01 | 2016-10-28 |
| Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib. Infanrix™/Hib, Infanrix, Hiberix - Tetanus, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 660 | 2007-01-03 | 2018-06-06 |
| Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. Boostrix - Tetanus, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 30 | 2007-01-01 | 2016-10-27 |
Showing 20 of 34. Sign in to see all of them.
Diphtheria (34) · Tetanus (34) · Poliomyelitis (16) · Haemophilus Infections (12) · Hepatitis B (8) · Whooping Cough (3) · Fever (1) · Influenza, Human (1) · Meningococcal Infections (1) · Pneumococcal Infections (1)
Actinomycetales Infections (34) · Bacterial Infections (34) · Bacterial Infections and Mycoses (34) · Clostridium Infections (34) · Corynebacterium Infections (34) · Gram-Positive Bacterial Infections (34) · Infections (34) · RNA Virus Infections (17) · Virus Diseases (17) · Central Nervous System Diseases (16) · Central Nervous System Infections (16) · Enterovirus Infections (16) · Myelitis (16) · Nervous System Diseases (16) · Neuroinflammatory Diseases (16)
Boostrix (9) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (9) · Diphtheria-Tetanus-acellular Pertussis Vaccines (5) · Tetanus Toxoid (5) · Hiberix (4) · DTPa-HBV-IPV combined vaccine (2) · Pentetic Acid (2) · RIX4414 vaccine (2) · adacel (2) · Diphtheria-Tetanus Vaccine (1) · Engerix-B (1) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · HibTITER protein, Haemophilus influenzae (1) · Measles-Mumps-Rubella Vaccine (1)
GlaxoSmithKline (34)
United States (9) · China (8) · Germany (2) · India (2) · South Korea (2) · Spain (2) · Vietnam (2) · Italy (1) · Poland (1) · Russia (1) · Singapore (1) · United Kingdom (1)